Hueston W J
Department of Family Medicine, University of Wisconsin-Madison Medical School, USA.
J Fam Pract. 1997 Mar;44(3):261-5.
Clinicians often prescribe antibiotics to treat acute bronchitis despite scant evidence that this approach is effective at speeding symptom resolution. Because patients infected with bacteria but not treated with antibiotics may need to return in the future for therapy, however, this approach may be cost effective.
To evaluate the cost of various treatment strategies to treat acute bronchitis, this study examined three different strategies including: (1) withholding antibiotics and treating only patients with persistent cough; (2) screening patients for Mycoplasma pneumoniae or Chlamydia pneumoniae and treating all patients with positive results with antibiotics; and (3) treating all patients with antibiotics. The cost analysis was approached from the patient's perspective. The main outcome measured was the cost per person in whom acute bronchitis was diagnosed.
Withholding antibiotics and treating only patients with a persistent cough was the most cost-effective strategy given the baseline assumptions. If the cost per patient visit was over $110, the cost of an initial course of antibiotics less than $2.72, or the prevalence of bacterial infection greater than 25%, then treatment of all patients was more cost effective. Assuming a screening test of 90% sensitivity and specificity, the screening strategy was only cost effective if the cost of the screening test was less than $2.35, or less than $3.80 if the test had no false-positive or false-negative results.
Under most circumstances, the most cost-effective strategy for treating acute bronchitis is to withhold antibiotics and treat only patients whose cough does not resolve.
尽管几乎没有证据表明使用抗生素治疗急性支气管炎能有效加速症状缓解,但临床医生仍经常开具抗生素。然而,由于感染细菌但未接受抗生素治疗的患者未来可能需要再次就诊接受治疗,所以这种方法可能具有成本效益。
为评估治疗急性支气管炎的各种治疗策略的成本,本研究考察了三种不同策略,包括:(1)不使用抗生素,仅治疗持续性咳嗽的患者;(2)对患者进行肺炎支原体或肺炎衣原体筛查,对所有检测结果呈阳性的患者使用抗生素治疗;(3)对所有患者使用抗生素治疗。成本分析从患者角度进行。主要测量结果是每例诊断为急性支气管炎的患者的成本。
根据基线假设,不使用抗生素仅治疗持续性咳嗽的患者是最具成本效益的策略。如果每次患者就诊成本超过110美元、初始抗生素疗程成本低于2.72美元或细菌感染患病率大于25%,那么对所有患者进行治疗更具成本效益。假设筛查试验的敏感性和特异性为90%,仅当筛查试验成本低于2.35美元时,筛查策略才具有成本效益;如果该试验无假阳性或假阴性结果,则成本低于3.80美元时筛查策略才具有成本效益。
在大多数情况下,治疗急性支气管炎最具成本效益的策略是不使用抗生素,仅治疗咳嗽未缓解的患者。